Objective. To understanding the molecular mechanisms in invasion andmetastasis of the ovarian carcinoma, we investigate a novel candidate metastasis―associated gene (MTA1) and nm23Hl mRNA expression and mutation in o...Objective. To understanding the molecular mechanisms in invasion andmetastasis of the ovarian carcinoma, we investigate a novel candidate metastasis―associated gene (MTA1) and nm23Hl mRNA expression and mutation in ovarian carcinoma. Methods. Twenty primary ovariancarcinoma specimens, 20 corresponding lymph nodes and 8 normal ovarian was examined for mRNAexpression and mutation of MTA1 and nm23Hl genes by reverse-transcription ploymerase chain reaction(RT―PCR) and RT―PCR―SSCP analysis. The level of the expression was determined by the relativeoptic desity (ROD) of the PCR products. Results. The frequency of MAT1 overexpression was 100% (7/7)in primary ovarian carcinoma with metastasis but only 38.5% (5/13) in those without metastasis(P=0.0103). Overexpression of MAT1 was observed in 87.5% (6/7) of lymph nodes with metastasis butonly 23% (3/13). of lymph nodes without metastasis (P=0.0118). In contrast with MAT1, low expressionof nm23H1 mRNA was seen in 7 of 7 o-varian carcinoma with metastasis but only in 4 of 13(30%) ofthose without metastassis (P=0.0043). Low nm23H1 expression was also seen in 7 of 7 lymph nodes withmetastasis but only in 5 of 13 (38.5%) nonmetastatic lymph nodes (P=0.0102). The ROD ratio of MAT1to nm23Hl increased with the development of metastasis. No mutation of MAT1 and nm23H1 genes wasfound by SSCP analysis. Conclusion. The mRNA expression of MTA1 and nm23H1 is positively andnegatively correlated with lymph node metastasis, respectively. Expression abnormalities but notmutation of the two genes are frequent events related to lymph node metastasis of ovarian cancer.展开更多
目的检测转移相关基因1（MTAl）蛋白在小细胞肺癌（SCLC）组织中的表达情况，探讨其在SCLC转移、预后和化疗敏感性预测中的作用。方法采用免疫组织化学法检测52例无远处转移SCLC组织标本中MTAl的表达，根据免疫组化结果分为两类：低表...目的检测转移相关基因1（MTAl）蛋白在小细胞肺癌（SCLC）组织中的表达情况，探讨其在SCLC转移、预后和化疗敏感性预测中的作用。方法采用免疫组织化学法检测52例无远处转移SCLC组织标本中MTAl的表达，根据免疫组化结果分为两类：低表达（≤6分）和高表达（〉6分）；分析MTAl表达水平与临床病理特征、EP方案（足叶乙甙100mg／in。静滴，d1-d5；顺铂60mg／m2静滴，d1，3周为1周期，共4-6个周期）化疗疗效及预后的关系。结果52例SCLC组织中MTAl高表达率为71．2％（37／52），18例癌旁组织均为低表达（100．0％）；MTAl表达在不同肿瘤直径、TNM分期、淋巴结转移与否和有无脉管侵犯之间的差异有统计学意义（P〈0．05），而在性别、年龄、VALG分期及肿瘤部位之间的差异无统计学意义（P〉0．05）；MTAl高表达组的EP方案化疗敏感率低于MTAl低表达组（54．1％ vs.80．0％，P=0．020）；MTAl低表达组的中位无进展生存期和总生存期均优于MTAl高表达组（20个月狐8个月，33个月 vs 35．18个月），差异有统计学意义（P〈0．05）。结论MTAl在SCLC组织中高表达，且与肿瘤转移、耐药及预后密切相关。展开更多
目的:探讨MTA1基因沉默对宫颈癌细胞转移增殖的影响。方法:用慢病毒转染法稳定转染Siha细胞,转染同时进行实验分组。用RT-PCR技术和蛋白印迹法测定宫颈癌Siha、Hela细胞中MTA1 m RNA和蛋白的表达。Transwell体外侵袭实验检测转染后Siha...目的:探讨MTA1基因沉默对宫颈癌细胞转移增殖的影响。方法:用慢病毒转染法稳定转染Siha细胞,转染同时进行实验分组。用RT-PCR技术和蛋白印迹法测定宫颈癌Siha、Hela细胞中MTA1 m RNA和蛋白的表达。Transwell体外侵袭实验检测转染后Siha细胞的迁移能力,MTT检测法和克隆形成实验法检测转染后Siha细胞的细胞增殖能力,FACS细胞凋亡法检测转染后Siha细胞的细胞凋亡率,PI-FACS细胞周期法检测转染后Siha细胞的各个生长周期的细胞数。结果:(1)Transwell体外侵袭实验:相比NC组,KD组Transwell转移率经T-Test分析P=2.61E-08<0.05。(2)MTT检测结果表明:相比NC组,KD组细胞增殖减缓。(3)克隆形成实验结果显示:相比NC组,KD组克隆数经T-Test分析P值=0.000 6<0.05。(4)FACS细胞凋亡:相比两个对照组,KD组凋亡率经T-Test分析P<0.05。结论:MTA1基因促进宫颈癌细胞的转移和增殖,沉默MTA1基因表达能使宫颈癌细胞增殖及迁移能力下降,加速宫颈癌细胞的凋亡,为抑制肿瘤转移奠定实验基础,最后为宫颈癌的新型药物性靶向治疗提供有力的实验依据。展开更多
文摘Objective. To understanding the molecular mechanisms in invasion andmetastasis of the ovarian carcinoma, we investigate a novel candidate metastasis―associated gene (MTA1) and nm23Hl mRNA expression and mutation in ovarian carcinoma. Methods. Twenty primary ovariancarcinoma specimens, 20 corresponding lymph nodes and 8 normal ovarian was examined for mRNAexpression and mutation of MTA1 and nm23Hl genes by reverse-transcription ploymerase chain reaction(RT―PCR) and RT―PCR―SSCP analysis. The level of the expression was determined by the relativeoptic desity (ROD) of the PCR products. Results. The frequency of MAT1 overexpression was 100% (7/7)in primary ovarian carcinoma with metastasis but only 38.5% (5/13) in those without metastasis(P=0.0103). Overexpression of MAT1 was observed in 87.5% (6/7) of lymph nodes with metastasis butonly 23% (3/13). of lymph nodes without metastasis (P=0.0118). In contrast with MAT1, low expressionof nm23H1 mRNA was seen in 7 of 7 o-varian carcinoma with metastasis but only in 4 of 13(30%) ofthose without metastassis (P=0.0043). Low nm23H1 expression was also seen in 7 of 7 lymph nodes withmetastasis but only in 5 of 13 (38.5%) nonmetastatic lymph nodes (P=0.0102). The ROD ratio of MAT1to nm23Hl increased with the development of metastasis. No mutation of MAT1 and nm23H1 genes wasfound by SSCP analysis. Conclusion. The mRNA expression of MTA1 and nm23H1 is positively andnegatively correlated with lymph node metastasis, respectively. Expression abnormalities but notmutation of the two genes are frequent events related to lymph node metastasis of ovarian cancer.
文摘目的检测转移相关基因1（MTAl）蛋白在小细胞肺癌（SCLC）组织中的表达情况，探讨其在SCLC转移、预后和化疗敏感性预测中的作用。方法采用免疫组织化学法检测52例无远处转移SCLC组织标本中MTAl的表达，根据免疫组化结果分为两类：低表达（≤6分）和高表达（〉6分）；分析MTAl表达水平与临床病理特征、EP方案（足叶乙甙100mg／in。静滴，d1-d5；顺铂60mg／m2静滴，d1，3周为1周期，共4-6个周期）化疗疗效及预后的关系。结果52例SCLC组织中MTAl高表达率为71．2％（37／52），18例癌旁组织均为低表达（100．0％）；MTAl表达在不同肿瘤直径、TNM分期、淋巴结转移与否和有无脉管侵犯之间的差异有统计学意义（P〈0．05），而在性别、年龄、VALG分期及肿瘤部位之间的差异无统计学意义（P〉0．05）；MTAl高表达组的EP方案化疗敏感率低于MTAl低表达组（54．1％ vs.80．0％，P=0．020）；MTAl低表达组的中位无进展生存期和总生存期均优于MTAl高表达组（20个月狐8个月，33个月 vs 35．18个月），差异有统计学意义（P〈0．05）。结论MTAl在SCLC组织中高表达，且与肿瘤转移、耐药及预后密切相关。
文摘目的:探讨MTA1基因沉默对宫颈癌细胞转移增殖的影响。方法:用慢病毒转染法稳定转染Siha细胞,转染同时进行实验分组。用RT-PCR技术和蛋白印迹法测定宫颈癌Siha、Hela细胞中MTA1 m RNA和蛋白的表达。Transwell体外侵袭实验检测转染后Siha细胞的迁移能力,MTT检测法和克隆形成实验法检测转染后Siha细胞的细胞增殖能力,FACS细胞凋亡法检测转染后Siha细胞的细胞凋亡率,PI-FACS细胞周期法检测转染后Siha细胞的各个生长周期的细胞数。结果:(1)Transwell体外侵袭实验:相比NC组,KD组Transwell转移率经T-Test分析P=2.61E-08<0.05。(2)MTT检测结果表明:相比NC组,KD组细胞增殖减缓。(3)克隆形成实验结果显示:相比NC组,KD组克隆数经T-Test分析P值=0.000 6<0.05。(4)FACS细胞凋亡:相比两个对照组,KD组凋亡率经T-Test分析P<0.05。结论:MTA1基因促进宫颈癌细胞的转移和增殖,沉默MTA1基因表达能使宫颈癌细胞增殖及迁移能力下降,加速宫颈癌细胞的凋亡,为抑制肿瘤转移奠定实验基础,最后为宫颈癌的新型药物性靶向治疗提供有力的实验依据。
